If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-21. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
== National differences and how to specialise == Australia In Australia, transfusion medicine is a sub-specialty of haematology. Training in transfusion medicine is covered by the Royal College of Pathologists of Australasia (RCPA). Australia has national blood services operated by the Australian Red Cross Blood Service. There are a series of guidelines and standards relevant to the laboratory released by the National Association of Testing Authorities, Australia (NATA), Australian and New Zealand Society of Blood Transfusion (ANZSBT) and RCPA. Similarly, there are a series of clinical practice, patient blood management guidelines by the National Blood Authority. In Australia, the Serious Transfusion Incident Reporting (STIR) system is in place to capture serious transfusion incidents and near-miss incidents.
== Reaction == In native chemical ligation, the ionized thiol group of an N-terminal cysteine residue of an unprotected peptide attacks the C-terminal thioester of a second unprotected peptide, in an aqueous buffer at pH 7.0 and room temperature. This transthioesterification step is reversible in the presence of an aryl thiol catalyst, rendering the reaction both chemoselective and regioselective, and leads to formation of a thioester-linked intermediate. The intermediate rapidly and spontaneously rearranges by an intramolecular S,N-acyl shift that results in the formation of a native amide ('peptide') bond at the ligation site (scheme 1).
The Medical Companion, Or Family Physician, a book from 1827, gave the following recipe: Paregoric Elixir – Take of purified opium, flowers of Benzoin, camphor, and essential oil of annis-seed, each, two drachms; brandy, two pints. Digest for eight or ten days, frequently shaking the bottle, and then strain the elixir.
Sources: en.wikipedia.org
On 6 May 1978, Operation Reindeer was condemned by United Nations Security Council Resolution 428, which described it as a violation of Angola's territorial integrity and threatened punitive measures should the SADF attempt another incursion on Angolan soil. The resolution attracted almost unanimous support worldwide, and was endorsed not only by the Soviet Union, but by major Western powers such as the US, the UK, France, Canada, and West Germany. As the Cassinga incident received publicity, American and European attitudes became one of intense criticism of South African purpose as well as the process by which it carried out the war. Notably, Western pressure at the UN to recognise South Africa as an equal partner in any future Namibian peace settlement evaporated. Cassinga was a major political breakthrough for SWAPO, which had portrayed the casualties there as martyrs of a Namibian nation in the making. The movement received unprecedented support in the form of humanitarian aid sent to its remaining refugee camps and offers from foreign governments to educate refugees in their countries.
Lightweight demand helmets are rigid structures which fully enclose the head of the diver and supply breathing gas "on demand". The flow of gas from the supply line is activated by inhalation reducing the pressure in the helmet to slightly below ambient, and a diaphragm in the demand valve senses this pressure difference and moves a lever to open the valve to allow breathing gas to flow into the helmet. This flow continues until the pressure inside the helmet again balances the ambient pressure and the lever returns to the shut position. This is exactly the same principle as used for scuba demand valves, and in some cases the same internal components are used. Sensitivity of the lever can often be adjusted by the diver by turning a knob on the side of the demand valve. Lightweight demand helmets are available in open circuit systems (used when breathing standard air) and closed circuit (reclaim) systems (which may be used in order to reduce costs when breathing mixed gas such as heliox and trimix: the exhaled gas is returned to the surface, scrubbed of carbon dioxide, re-oxygenated, recompressed into storade cylinders and may be returned to the diver or used for a later dive). The helmet may be of metal or reinforced plastic composite (GRP), and is either connected to a neck dam or clamped directly to a dry suit. The neck dam is the lower part of the helmet, which seals against the neck of the diver in the same way that the neck seal of a dry suit works. Neck dams may have neoprene or latex seals, depending on diver preference.
Non-aqueous phase liquids, or NAPLs, are organic liquid contaminants characterized by their relative immiscibility with water. Common examples of NAPLs are petroleum products, coal tars, chlorinated solvents, and pesticides. Strategies employed for their removal from the subsurface environment have expanded since the late-20th century. NAPLs can be released into the environment from a variety of point sources such as improper chemical disposal, leaking underground storage tanks, septic tank effluent, and percolation from spills or landfills. The movement of NAPLs within the subsurface environment is complex and difficult to characterize. Nonetheless, the various parameters that dictate their movement are important to understand in order to determine appropriate remediation strategies. These strategies use NAPLs' physical, chemical, and biological properties to minimize their presence in the subsurface.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.